Adenosine Derivative and Capsid Inhibitor HIV Combination Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing HIV treatments face challenges due to virus resistance and medication adherence issues, necessitating new long-acting compounds and combinations to effectively inhibit reverse transcriptase and reduce dosing frequency.
Innovation Solution
A combination therapy using adenosine derivatives and capsid inhibitors administered to treat HIV infection, targeting reverse transcriptase and potentially reducing dosing frequency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If combination therapy with adenosine derivative and capsid inhibitor is used, then antiretroviral efficacy is improved, but risk of resistance development increases
Solution Approach 1:
The patent divides the antiretroviral treatment into two distinct functional components: adenosine derivatives that block reverse transcription and capsid inhibitors that prevent nuclear import. This segmentation targets different stages of the HIV lifecycle independently, allowing each component to address specific viral mechanisms while collectively improving efficacy and reducing resistance risk.
Solution Approach 2:
The patent creates a composite therapeutic approach by combining two chemically and mechanistically distinct agents (adenosine derivatives and capsid inhibitors) into a unified treatment regimen. This composite strategy leverages the complementary mechanisms of action to achieve synergistic antiretroviral effects while minimizing the development of resistance through multiple simultaneous targets.
2Productivity
If adenosine derivative alone is used, then viral replication is inhibited, but resistance develops rapidly
Solution Approach 1:
The patent employs adenosine derivatives to preliminarily block reverse transcription, preventing the virus from converting its RNA into DNA. This preliminary action occurs at an early stage of viral replication, reducing the viral load before the capsid inhibitor acts to block nuclear import, thereby creating a multi-layered defense that slows resistance development.
Solution Approach 2:
The capsid inhibitor serves as an intermediary mechanism that complements the adenosine derivative. While the adenosine derivative directly inhibits reverse transcription, the capsid inhibitor mediates an additional block by preventing the viral capsid from transporting genetic material into the nucleus, creating a coordinated two-step inhibition strategy.
3Productivity
If capsid inhibitor alone is used, then nuclear import is blocked, but monotherapy leads to treatment failure
Solution Approach 1:
The patent merges two previously separate monotherapy approaches (adenosine derivative monotherapy and capsid inhibitor monotherapy) into a combined regimen. This merging allows the treatment to leverage both the reverse transcription blocking capability and the nuclear import blocking capability, creating a more robust and reliable antiretroviral therapy that overcomes the limitations of either agent used alone.
Data Source
Figure 1
AI summary
The present disclosure is directed to methods of treating or preventing RNA virus infections and retroviral diseases, such as HIV and AIDS, comprising administering to a subject in need an effective amount of (a) a capsid inhibitor and (b) an adenosine derivative disclosed herein. Compositions comprising an effective amount of an adenosine derivative and an effective amount of a capsid (CA) inhibitor are also provided.